ICU Medical, Inc. — 2015 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2015; quarterly figures for Q4 are unaudited. ICU Medical develops and sells medical devices for infusion therapy, critical care and oncology. Its products are sold in more than 60 countries. Infusion therapy generated 72% of 2015 revenue, critical care 16% and oncology 12%.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Total revenue | $341.7 million | $309.3 million | +10.5% |
| Gross profit / margin | $180.8 million / 52.9% | $151.4 million / 49.0% | Margin +3.9 pts |
| Operating income / margin | $68.6 million / 20.1% | $39.0 million / 12.6% | +75.7% |
| Net income / diluted EPS | $45.0 million / $2.73 | $26.3 million / $1.68 | Net income +70.8% |
| Cash from operations | $54.9 million | $60.6 million | −9.5% |
| Cash, equivalents and investments | $377.4 million | $346.8 million | +$30.6 million |
2015 working capital was $462.4 million; current assets were $505.0 million and current liabilities $42.6 million. The balance sheet reports no borrowings; long-term liabilities were $1.5 million. Total assets were $626.8 million and stockholders’ equity $579.9 million. Capital expenditures were $13.0 million. Management expects 2016 capital expenditures of approximately $18–20 million.
Revenue by product line: infusion therapy $244.8 million, up 13%; critical care $54.3 million, down 1%; oncology $41.4 million, up $4.7 million. Infusion growth reflected new customers and higher volumes from existing customers. Gross margin improved on favorable product and customer mix, operating efficiencies and favorable foreign-exchange effects on operating costs.
In Q4 2015, revenue was $90.4 million versus $79.9 million in Q4 2014; net income was $5.5 million versus $7.4 million. The filing does not clearly allocate the full-year unusual items to individual quarters or explain the Q4 net-income decline.
Material changes, outlook and risks
- Pfizer, following its acquisition of Hospira, accounted for 36% of worldwide revenue in 2015, unchanged from 2014; Pfizer-related accounts receivable were 40% of year-end receivables. The agreements run through December 2018. ICU Medical cautions that future purchasing and the relationship are uncertain; Pfizer announced plans to promote a competing needlefree valve in some foreign markets.
- In October 2015, ICU Medical acquired EXC Holding for approximately $59.5 million cash, then sold certain acquired assets for approximately $29.0 million. It retained the SwabCap disinfection-cap business. Management expects a minimal first-year EPS contribution and a greater return on invested capital after the first year.
- The company began closing its Slovakia manufacturing facility and transferring production principally to Mexico, with completion expected in the second half of 2016. Related 2015 charges included $4.1 million impairment of assets held for sale and restructuring costs. Execution, production continuity and Mexican labor availability and costs are risks.
- Other 2015 items included $8.5 million of combined restructuring and strategic transaction expense, a $1.1 million building-sale gain and $1.8 million net legal-settlement expense. The net legal amount included an award to Hospira and a separate recovery from a service provider.
- Management expects existing cash, investments and operating cash generation to fund operations for at least the next 12 months. The company does not anticipate repatriating $32.6 million of cash held by foreign subsidiaries to fund U.S. operations.
- Key risks include customer concentration, competitive and healthcare pricing pressure, product and regulatory approval risks, patent disputes and expirations, reliance on limited or sole-source suppliers, manufacturing-site disruption, international credit and currency exposure, and product liability. The company does not hedge foreign-currency exposure. The medical-device excise tax was suspended for two years beginning January 2016; management expected it to resume in 2018 absent a change in law.
- The financial statements received an unqualified audit opinion, and the auditor reported effective internal control over financial reporting as of year-end.
Important facts for investors to verify
- Whether Pfizer’s post-acquisition purchasing, distribution strategy and competing-product plans change ICU Medical’s sales, pricing or contract position.
- Whether SwabCap integration and the Medline agreement deliver the expected growth and returns after the first year.
- Whether the Slovakia closure and transfer to Mexico finish on schedule without production disruption or materially higher costs.
- Whether working-capital demands, especially receivables and inventory, reverse or continue to constrain operating cash flow.
- How much of the 2015 operating-income improvement is sustainable after separating margin and expense improvements from one-time legal, restructuring, impairment and transaction items.
- Whether the medical-device excise tax resumes in 2018 and whether currency, supplier, regulatory or litigation developments materially affect results.